<DOC>
	<DOCNO>NCT01416402</DOCNO>
	<brief_summary>The purpose study determine whether arhalofenate safe effective dose combination febuxostat lower serum uric acid patient gout .</brief_summary>
	<brief_title>Open Label Safety/Efficacy Study Arhalofenate Combination With Febuxostat Hyperuricemia Gout Patients</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>1 . Known gout patient ( per criterion American Rheumatism Association classification acute arthritis primary gout Appendix 3 ) serum uric acid value least 8.0 mg/dL Screening Visit . Patients allopurinol must agree discontinue exist therapy Visit 1 entire duration study must sUA value least 8.0 mg/dL minimum 2 week washout Visit 2 . 2 . Male female , 1875 year age Screening Visit 3 . All female patient must surgically sterile postmenopausal ( least 45 year age history menses least 2 year ; age history menses least 6 month serum FSH ≥ 40 mIU/mL ) must agree use two medically accept method contraception include barrier method ( see list Appendix 4 ) entire duration study unless report complete sexual abstinence . 4 . Female patient must pregnant lactate 5 . Male patient female partner childbearing potential must agree use condom partner must use medically acceptable method contraception entire duration study . 6 . Estimated CrCl ≥ 50 mL/min calculate CockcroftGault method 7 . Serum creatinine value must ≤ 1.3 mg/dL female ≤ 1.4 mg/dL male 8 . Patients must liver function test ( LFTs ) ≤ 1.5X ULN AST , ALT Tbilirubin , ≤ 2X ULN ALP , ≤ 3X ULN GGT ; CK ≤ 3X ULN 9 . All clinical laboratory parameter must within normal limit consider clinically significant 10 . Electrocardiogram ( ECG ) must normal , abnormal , consider clinically significant 11 . Patients must systolic blood pressure ≤ 160 mm Hg diastolic blood pressure ≤ 95 mm Hg ; know hypertensive patient control medication diuretic ( BP read ) may include 12 . Patients must agree remain inclinic 37 day consecutively agree follow study procedure describe protocol 1 . Treatment ULT allopurinol ( e.g. , probenecid , benzbromarone , febuxostat , pegloticase ) within two week Screening Visit 2 . Known suspected secondary hyperuricemia ( e.g . due myeloproliferative disorder , organ transplant ) . 3 . Diagnosis xanthinuria 4 . History document suspected kidney stone 5 . Known infection human immunodeficiency virus ( HIV ) history viral hepatitis type B C 6 . History illicit drug alcohol abuse within one year Screening Visit 7 . History significant pulmonary disease , upper gastrointestinal ( GI ) bleeding , document peptic ulcer disease ( unless know H. pylori infection treat successfully without recurrence ) , nephrotic syndrome within three year Screening Visit 8 . History stroke , TIA , acute myocardial infarction ( MI ) , congestive heart failure ( CHF ) ( NYHA Class IIIV ) , angina pectoris , coronary intervention procedure ( include limit angioplasty , stent placement , coronary revascularization ) , low extremity bypass procedure , systemic intracoronary fibrinolytic therapy within 5 year screen 9 . Malignancy within five year Screening Visit ( except successfully treat basal cell carcinoma ) 10 . Body mass index ( BMI ) &gt; 42 kg/m2 11 . Current expect requirement anticoagulant therapy [ except lowdose ( ≤ 325 mg/day ) aspirin and/or Plavix® 75 mg/day ] 12 . Rheumatoid arthritis autoimmune disease require ongoing treatment 13 . Current expect treatment potent CYP3A4 inhibitor ( See Appendix 6 ) , cytotoxic agent ( azathioprine , mercaptopurine , cyclosporine , cyclophosphamide , etc . ) , ranolazine , digoxin , theophyline , desipramine , sulphonylurea , thiazolidinedione , diuretic , atypical antipsychotic agent , phenytoin 14 . Chronic treatment nonsteroidal antiinflammatory drug ( NSAIDs use treat acute gout flare permit ) 15 . Current expect treatment systemic corticosteroid ( except topical , ophthalmic , intraarticular , inhale dose &lt; 1600 μg/day ) treat acute gout flare 16 . Known hypersensitivity colchicine febuxostat 17 . Treatment investigational therapy within 30 day prior Screening Visit , patient receive least one dose blind study medication enrol previous arhalofenate trial 18 . Any condition compromise ability patient provide inform consent comply objectives procedure protocol , judge investigator and/or medical monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hyperuricemia</keyword>
	<keyword>gout</keyword>
	<keyword>serum uric acid</keyword>
</DOC>